DE69128774T3 - GEREINIGTE IgG ANTIKÖRPER - Google Patents

GEREINIGTE IgG ANTIKÖRPER Download PDF

Info

Publication number
DE69128774T3
DE69128774T3 DE69128774T DE69128774T DE69128774T3 DE 69128774 T3 DE69128774 T3 DE 69128774T3 DE 69128774 T DE69128774 T DE 69128774T DE 69128774 T DE69128774 T DE 69128774T DE 69128774 T3 DE69128774 T3 DE 69128774T3
Authority
DE
Germany
Prior art keywords
antibody
column
protein
campath
size exclusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69128774T
Other languages
German (de)
English (en)
Other versions
DE69128774T2 (de
DE69128774D1 (de
Inventor
Paul Ian Nicholas Ramage
Geoffrey Langley Court Allen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69128774(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE69128774D1 publication Critical patent/DE69128774D1/de
Publication of DE69128774T2 publication Critical patent/DE69128774T2/de
Publication of DE69128774T3 publication Critical patent/DE69128774T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69128774T 1990-10-17 1991-10-17 GEREINIGTE IgG ANTIKÖRPER Expired - Lifetime DE69128774T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9022547 1990-10-17
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin
PCT/GB1991/001816 WO1992007084A1 (en) 1990-10-17 1991-10-17 Purified cdw52-specific antibodies

Publications (3)

Publication Number Publication Date
DE69128774D1 DE69128774D1 (de) 1998-02-26
DE69128774T2 DE69128774T2 (de) 1998-06-04
DE69128774T3 true DE69128774T3 (de) 2007-08-16

Family

ID=10683866

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69128774T Expired - Lifetime DE69128774T3 (de) 1990-10-17 1991-10-17 GEREINIGTE IgG ANTIKÖRPER

Country Status (29)

Country Link
US (1) US5644036A (enExample)
EP (1) EP0504363B2 (enExample)
JP (1) JP2638680B2 (enExample)
KR (2) KR960015399B1 (enExample)
AT (2) ATE162552T1 (enExample)
AU (3) AU658926B2 (enExample)
BE (1) BE1004226A5 (enExample)
BR (1) BR1100358A (enExample)
CA (1) CA2069481C (enExample)
CH (2) CH681305A5 (enExample)
DE (1) DE69128774T3 (enExample)
DK (1) DK0504363T4 (enExample)
ES (2) ES2112865T5 (enExample)
FI (2) FI110003B (enExample)
FR (2) FR2668164A1 (enExample)
GB (2) GB9022547D0 (enExample)
GR (3) GR910100425A (enExample)
HU (1) HUT64601A (enExample)
IE (1) IE913560A1 (enExample)
IL (3) IL99761A0 (enExample)
IT (1) IT1250064B (enExample)
LU (1) LU88122A1 (enExample)
MX (1) MX9203794A (enExample)
MY (2) MY136210A (enExample)
NZ (2) NZ240247A (enExample)
PT (2) PT99248B (enExample)
TW (1) TW283710B (enExample)
WO (1) WO1992007084A1 (enExample)
ZA (2) ZA918259B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
EP0610447B1 (en) * 1991-10-15 1998-12-16 Btg International Limited CDw52 - SPECIFIC ANTIBODY FOR TREATMENT OF T-CELL MEDIATED INFLAMMATION OF THE JOINTS
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
DE69626022T3 (de) † 1995-08-01 2008-05-08 Sanofi Pasteur Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
ES2266535T3 (es) * 2001-06-05 2007-03-01 Genetics Institute, Llc Procedimientos relativos a la purificacion de proteinas altamente anionicas.
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
ES2626268T3 (es) 2002-09-11 2017-07-24 Chugai Seiyaku Kabushiki Kaisha Método de purificación de proteínas
EP2314603A3 (en) 2002-10-15 2011-05-18 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
JP2007515492A (ja) * 2003-12-22 2007-06-14 ジェンザイム コーポレイション 糖尿病の抗ｃｄ５２抗体治療法
DK1869065T3 (da) * 2005-03-11 2020-06-08 Wyeth Llc Fremgangsmåde til kromatografi med svag opdeling
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2010132683A1 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treating lupus
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
US20130178608A1 (en) * 2009-12-29 2013-07-11 Samir Kulkarni Protein purification by ion exchange
JP5873016B2 (ja) 2010-06-21 2016-03-01 協和発酵キリン株式会社 アミノ酸を利用したタンパク質の精製方法
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR102344170B1 (ko) 2013-12-27 2021-12-27 추가이 세이야쿠 가부시키가이샤 등전점이 낮은 항체의 정제방법
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2017022651A1 (ja) 2015-07-31 2017-02-09 中外製薬株式会社 アニオン性ポリマーによる抗体を含有する組成物の精製方法
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US10688412B2 (en) 2016-07-25 2020-06-23 Cehpalon, Inc. Affinity chromatography wash buffer
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
EP3950099A4 (en) 2019-03-29 2022-05-18 Asahi Kasei Medical Co., Ltd. PROTEINS PURIFICATION PROCEDURES
CN113692420B (zh) 2019-04-08 2023-09-12 旭化成医疗株式会社 用于纯化含蛋白质的溶液的聚酰胺介质及其制造方法
AU2020273072B2 (en) 2019-04-10 2026-01-22 Chugai Seiyaku Kabushiki Kaisha Method for purifying Fc region-modified antibody
JPWO2022260091A1 (enExample) 2021-06-10 2022-12-15

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
DE68909441T2 (de) * 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.

Also Published As

Publication number Publication date
GR910100425A (el) 1992-09-25
ATE162552T1 (de) 1998-02-15
ITRM910788A1 (it) 1993-04-16
JPH05504579A (ja) 1993-07-15
DK0504363T3 (da) 1998-09-21
GR920100471A (el) 1994-06-30
FR2677997A1 (fr) 1992-12-24
GB9209529D0 (en) 1992-07-01
AU4521897A (en) 1998-02-12
ATA900791A (de) 1996-06-15
ES2112865T5 (es) 2007-09-16
MX9203794A (es) 1992-07-01
FI922380L (fi) 1992-05-25
IL102726A0 (en) 1993-01-31
NZ244114A (en) 1995-06-27
CH681305A5 (enExample) 1993-02-26
BE1004226A5 (fr) 1992-10-13
ES2081742B1 (es) 1996-10-01
ES2081742A1 (es) 1996-03-01
HUT64601A (en) 1994-01-28
DE69128774T2 (de) 1998-06-04
AU716402B2 (en) 2000-02-24
US5644036A (en) 1997-07-01
GB2253397A (en) 1992-09-09
FI922824L (fi) 1992-06-17
GB9022547D0 (en) 1990-11-28
ZA926191B (en) 1993-04-16
MY136210A (en) 2008-08-29
FI922380A0 (fi) 1992-05-25
FI110003B (fi) 2002-11-15
AU649078B2 (en) 1994-05-12
PT99248A (pt) 1993-06-30
IE913560A1 (en) 1992-04-22
FR2668164B1 (enExample) 1995-04-14
ZA918259B (en) 1993-04-16
PT100988A (pt) 1994-02-28
AU2532192A (en) 1993-02-11
LU88122A1 (fr) 1993-03-15
KR100193314B1 (ko) 1999-06-15
TW283710B (enExample) 1996-08-21
PT99248B (pt) 1999-04-30
AU8729491A (en) 1992-05-20
AU658926B2 (en) 1995-05-04
HU9202000D0 (en) 1992-10-28
KR920703108A (ko) 1992-12-17
BR1100358A (pt) 2000-03-28
ITRM910788A0 (it) 1991-10-16
JP2638680B2 (ja) 1997-08-06
EP0504363B2 (en) 2007-02-07
EP0504363B1 (en) 1998-01-21
EP0504363A1 (en) 1992-09-23
DK0504363T4 (da) 2007-05-29
CH681455A5 (enExample) 1993-03-31
CA2069481A1 (en) 1992-04-18
PT100988B (pt) 1999-08-31
NZ240247A (en) 1994-03-25
FI110002B (fi) 2002-11-15
GR3026588T3 (en) 1998-07-31
FR2668164A1 (fr) 1992-04-24
IL102726A (en) 2002-08-14
WO1992007084A1 (en) 1992-04-30
KR960015399B1 (ko) 1996-11-13
CA2069481C (en) 2003-07-29
IT1250064B (it) 1995-03-30
IL99761A0 (en) 1992-08-18
FI922824A0 (fi) 1992-06-17
AU7024294A (en) 1995-01-05
ES2112865T3 (es) 1998-04-16
DE69128774D1 (de) 1998-02-26
MY119030A (en) 2005-03-31

Similar Documents

Publication Publication Date Title
DE69128774T2 (de) GEREINIGTE IgG ANTIKÖRPER
DE69133472T2 (de) Antikörper und ihre therapeutische Verwendung
DE68921364T2 (de) Verfahren zur Herstellung von Proteinen mittels rekombinanter DNA.
DE69223641T2 (de) Stabilisierte antikörper
DE68928641T2 (de) Menschliches IFN-beta2/IL-6, dessen Reinigung und Verwendungen
DE69636733T2 (de) Antikörperreinigung durch hydrophobe wechselwirkungchromatografie bei niedrigem ph
DE69031410T2 (de) Monoklonale Antikörper gegen den humanen alpha/beta-T-Zellenrezeptor, ihre Herstellung und Verwendung
DE69100768T2 (de) CD25-bindende Moleküle.
DE102010039018B4 (de) Anti-La Antikörper und ihre Anwendung zum Immunotargeting
IE84931B1 (en) Purified IgG Antibodies
DE69133200T2 (de) Spezifisch bindende Agentien
DE69028095T2 (de) M-csf-monoklonale antikörper, die ein neutralisierendes konformationales epitop erkennen
DE69020112T2 (de) Spezifische bindende Wirkstoffe.
DE69028713T3 (de) Schimäre immunoglobuline für cd4-rezeptoren
DE69020914T2 (de) Monoklonale Antikörper von Ratten gegen menschliche Antigene und Verfahren zu deren Herstellung.
EP0133551A2 (de) Monoklonaler Antikörper, der eine Struktur erkennt die dem Human-Interleukin-2 (TCGF) und der leichten Kette "lambda" von Humanimmunglobulin gemeinsam ist, und Hybridoma-Zell-Linien, die diese monoklonalen Antikörper produzieren
DE68913793T2 (de) Ein von einem Human-Human-Hybridom abgeleiteter monoklonaler Antikörper und dessen Verwendung.
AU649078C (en) Purified CDW52-specific antibodies
AT396936B (de) Hybridoma zell-linien und verfahren zu ihrer herstellung sowie die verwendung der genannten zell-linien zur herstellung von monoklonalen antikörpern
DE69231058T2 (de) Hochaffine humanisierte monoklonale antikoerper
DE68924963T2 (de) Zusammensetzungen und Methoden zur Behandlung und Vorbeugung von Gram-Negativen-Infektionen.
DE3719398A1 (de) Liganden und verfahren zur vermehrung der b-zellen-proliferation
DD230883B1 (de) Verfahren zur herstellung monoklonaler antikoerper fuer humanes iga

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings